MedTrace Logo

Amifostine Plus Topotecan in Treating Patients With Myelodysplastic Syndrome

NCT00003415 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 26

Last updated 2013-01-31

No results posted yet for this study

Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Chemoprotective drugs such as amifostine may protect normal cells from the side effects of chemotherapy.

PURPOSE: Phase I/II trial to study the effectiveness of amifostine plus topotecan in treating patients with myelodysplastic syndrome.

Conditions

Interventions

DRUG

amifostine trihydrate

DRUG

topotecan hydrochloride

Sponsors & Collaborators

  • University of Arizona

    lead OTHER

Principal Investigators

  • Alan F. List, MD · University of Arizona

Study Design

Purpose
TREATMENT

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
1998-09-30
Completion
2002-11-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00003415 on ClinicalTrials.gov